After finishing at $7.21 in the prior trading day, IGM Biosciences Inc. (NASDAQ: IGMS) closed at $7.36, up 2.08%. In other words, the price has increased by $+0.15 from its previous closing price. On the day, 636323 shares were traded. IGMS stock price reached its highest trading level at $7.39 during the session, while it also had its lowest trading level at $7.00.
Our goal is to gain a better understanding of IGMS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.10 and its Current Ratio is at 9.10. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 03 when Gauthier George sold 936 shares for $9.42 per share. The transaction valued at 8,818 led to the insider holds 40,017 shares of the business.
Topsoe Jakob Haldor bought 3,500 shares of IGMS for $32,375 on Jun 30. The Director now owns 81,644 shares after completing the transaction at $9.25 per share. On Jun 30, another insider, Topsoe Christina Teng, who serves as the Director of the company, bought 3,000 shares for $9.32 each. As a result, the insider paid 27,957 and bolstered with 9,800 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGMS now has a Market Capitalization of 429.57M and an Enterprise Value of 84.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 247.51 while its Price-to-Book (P/B) ratio in mrq is 1.28. Its current Enterprise Value per Revenue stands at 52.87 whereas that against EBITDA is -0.36.
Stock Price History:
Over the past 52 weeks, IGMS has reached a high of $28.20, while it has fallen to a 52-week low of $6.45. The 50-Day Moving Average of the stock is 8.62, while the 200-Day Moving Average is calculated to be 14.36.
The stock has traded on average 296.16K shares per day over the past 3-months and 280.64k shares per day over the last 10 days, according to various share statistics. A total of 45.12M shares are outstanding, with a floating share count of 21.42M. Insiders hold about 1.00% of the company’s shares, while institutions hold 61.60% stake in the company. Shares short for IGMS as of Aug 30, 2023 were 5.64M with a Short Ratio of 5.64M, compared to 4.88M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.67% and a Short% of Float of 37.23%.
Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$1.24 for the current quarter, with a high estimate of -$1.05 and a low estimate of -$1.49, while EPS last year was -$1.32. The consensus estimate for the next quarter is -$1.28, with high estimates of -$1.08 and low estimates of -$1.54.
Analysts are recommending an EPS of between -$3.94 and -$5.77 for the fiscal current year, implying an average EPS of -$5.13. EPS for the following year is -$4.5, with 11 analysts recommending between -$2.92 and -$6.46.
10 analysts predict $780k in revenue for the current quarter. It ranges from a high estimate of $1.01M to a low estimate of $450k. As of the current estimate, IGM Biosciences Inc.’s year-ago sales were $250k, an estimated increase of 212.00% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $870k, an increase of 133.90% less than the figure of $212.00% in the same quarter last year. There is a high estimate of $1.28M for the next quarter, whereas the lowest estimate is $450k.
A total of 11 analysts have provided revenue estimates for IGMS’s current fiscal year. The highest revenue estimate was $3M, while the lowest revenue estimate was $1.87M, resulting in an average revenue estimate of $2.66M. In the same quarter a year ago, actual revenue was $1.07M, up 148.80% from the average estimate.